Fig. 2From: Incidence and immunomic features of apyretic COVID-19 in patients affected by solid tumors: a prospective cohort studyPBMCs transcriptomic profile assessed on peripheral blood samples collected from two positive patients for SARS-CoV-2 IgM at baseline (T1), 2 months (T2), and 7 months (T3) from the first serology. The top 5 depleted (A) and enriched (B) immunologic signatures with the highest variance across samples were selected for the transcriptomic analysisBack to article page